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 The Treatment of Psychotic Major Depression:
Is There a Role for Adjunctive Psychotherapy? 
 Brandon A. Gaudiano   a     Ivan W. Miller   a     James D. Herbert   b   
  a   Department of Psychiatry and Human Behavior, Brown Medical School and Butler Hospital,  Providence, R.I. , and 
 b 
  Department of Psychology, Drexel University,  Philadelphia, Pa. , USA 
 There are several empirically supported biological and 
psychosocial treatment options currently available for in-
dividuals suffering from major depression. However, de-
pression is a heterogeneous condition, and far less re-
search has been conducted on the adaptation of treat-
ments for specific diagnostic subtypes. Population studies 
estimate that psychotic features (i.e. hallucinations and/
or delusions) are present in 14–19% of patients with major 
depression, giving it a lifetime population prevalence of 
over 2%  [1, 2] . The rates tend to be particularly high in 
hospitalized depressed patients, with up to 25% meeting 
criteria for psychotic depression (PD)  [3] . In this paper, 
we review the clinical features of PD and present the pre-
liminary data to date on psychotherapy response in pa-
tients with PD. We then briefly discuss research and 
treatment implications based on current empirical knowl-
edge.
 Clinical Features and Course of PD 
 Patients with PD can be differentiated from those with 
nonpsychotic depression based on a number of neurobio-
logical and neuropsychological abnormalities, including 
distinct patterns of structural brain anomalies, hypotha-
lamic-pituitary-adrenocortical axis activity, dopamine 
and serotonin neurotransmission, and cognitive deficits 
 [4–6] . Other clinical characteristics of PD include greater 
symptom severity, number of suicide attempts, psycho-
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 Abstract 
 Background: Psychotic depression is a relatively prevalent 
mood disorder associated with greater symptom severity, a 
poorer course of illness and higher levels of functional im-
pairment compared with nonpsychotic depression. Sepa-
rate lines of investigation suggest that various forms of cog-
nitive-behavioral therapy are efficacious for treating severe 
forms of nonpsychotic depression as well as primary psy-
chotic disorders. However, there currently are no empirically 
supported psychotherapies specifically designed for treat-
ing psychotic depression.  Method: We review the efficacy of 
current somatic treatments for the disorder and discuss the 
limited data to date on potentially useful psychotherapeutic 
approaches. In particular, we describe the clinical improve-
ment observed in a subgroup of hospitalized patients with 
psychotic depression treated with Acceptance and Commit-
ment Therapy as part of a larger clinical trial.  Results: Pilot 
results demonstrated that Acceptance and Commitment 
Therapy was associated with clinically significant reductions 
in acute symptom severity and impairment compared with 
treatment as usual.  Conclusion: The findings suggest that 
patients with psychotic depression can benefit from psycho-
therapy. Clinical and research recommendations in this area 
are presented.  Copyright © 2007 S. Karger AG, Basel 
 
 Brandon A. Gaudiano
Psychosocial Research Program, Butler Hospital
345 Blackstone Boulevard
Providence, RI 02906 (USA)
Tel. +1 401 455 6457, Fax +1 401 455 6235, E-Mail Brandon_Gaudiano@brown.edu 
 © 2007 S. Karger AG, Basel
0033–3190/07/0765–0271$23.50/0 
 Accessible online at:
www.karger.com/pps 
 Gaudiano  /Miller  /Herbert  
 
Psychother Psychosom 2007;76:271–277272
motor disturbance, psychiatric comorbidity, axis II per-
sonality features and functional impairment  [3, 7–9] . 
Compared with nonpsychotic depression, PD is charac-
terized by a longer duration of illness, more frequent hos-
pitalizations and relapses and a greater likelihood of re-
current psychotic symptoms  [10–12] . Further, the poorer 
outcomes in PD have been shown to be independent of 
initial symptom severity, and patients continue to show 
poorer outcomes even after acute psychotic symptoms 
dissipate  [12–14] . Research suggests that clinicians often 
fail to thoroughly assess for psychotic symptoms and pa-
tients tend to underreport symptoms due to paranoia or 
embarrassment  [15] . The number of differences between 
psychotic and nonpsychotic subtypes has led some to ar-
gue that PD should be recognized as a unique diagnostic 
entity  [14] .
 Current Somatic Treatments for PD 
 Patients with PD show a poorer response to antide-
pressant treatment with tricyclic or selective serotonin 
reuptake inhibitor medications alone compared with 
nonpsychotic depressed individuals  [5, 6] . Many authors 
suggest that antidepressant plus antipsychotic treatment 
is superior to treatment with either medication alone, al-
though the results have not always been consistent. In a 
recent Cochrane Systematic Review, Wijkstra et al.  [16] 
concluded that currently there are insufficient data to 
support the superiority of combined antidepressant and 
antipsychotic treatment compared to antidepressant 
monotherapy. Additional evidence suggests that electro-
convulsive therapy is an efficacious treatment for PD. 
Electroconvulsive therapy is at least as effective and in 
fact may be even more effective than combined antide-
pressant plus antipsychotic therapy based on results from 
meta-analyses  [5, 17] . However, electroconvulsive thera-
py and neuroleptic medications have several disadvan-
tages that can limit their effectiveness in clinical practice, 
including side effects, safety concerns and symptom per-
sistence despite adequate treatment  [5, 17, 18] .
 Psychotherapy Response in PD 
 Given the limitations of current somatic treatments 
for PD, a clear role exists for psychosocial interventions 
that can be used adjunctively to treat this disorder. In one 
of the only reports of its kind, Bishop et al.  [19] described 
a case study detailing the successful treatment of a wom-
an with PD who refused to take medications using cogni-
tive therapy. However, we were unable to identify any 
full-scale clinical trials of psychotherapy specifically for 
PD. Cognitive behavior therapy (CBT) – a general term 
we use here to refer to the family of closely-related cogni-
tive and behavioral interventions – has been found to be 
efficacious either alone or in combination with medica-
tions to treat severe forms of depression  [20, 21] . Further, 
emerging evidence suggests that CBT produces medium 
effect size gains beyond ‘treatment as usual’ for patients 
with primary psychotic disorders  [22, 23] . Although 
some past research has included small numbers of pa-
tients with PD  [24] , the vast majority of psychotherapy 
studies have excluded these patients from trials.
 There also is a paucity of research investigating wheth-
er the poorer outcomes found in patients with psychotic 
versus nonpsychotic depression apply to treatments that 
include pharmacotherapy and psychotherapy. Gaudiano 
et al.  [13] recently reported response to combined treat-
ments in patients with PD. The data were pooled from 
clinical trials in which patients with psychotic and non-
psychotic major depression were provided with effica-
cious combined therapies (medication plus cognitive, be-
havioral or family therapies). Although similar in sever-
ity during acute hospitalization, patients with PD showed 
greater depression severity at postoutpatient treatment 
and at 6-month follow-up. Following treatment, patients 
with PD were over  4 times as likely to exhibit severe levels 
of suicidal ideation and depression. The findings indi-
cated that current state-of-the-art combined treatments 
may have poorer efficacy in depressed patients with psy-
chotic symptoms, suggesting the need for adapted treat-
ments better tailored to the needs of this population.
 Pilot Findings Using an Acceptance-Based 
Psychotherapy for PD 
 Treatment Rationale and Description 
 Feasibility data for the psychosocial treatment of PD 
can be found in recent research using a brief form of Ac-
ceptance and Commitment Therapy (ACT)  [25] to treat 
acutely ill patients with psychotic spectrum disorders. 
ACT is similar to other emerging behavioral approaches 
that incorporate acceptance and mindfulness elements, 
such as dialectical behavior therapy  [26] . Preliminary ev-
idence from over 10 preliminary randomized trials sug-
gests the efficacy of ACT for treating a wide variety of 
problems, including anxiety and substance use disorders 
 [27] . The results from 2 small trials comparing ACT to 
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traditional CBT in depressed outpatients found that both 
produced similar improvements in depression by post-
treatment, but that ACT resulted in earlier changes in the 
believability of negative cognitions  [27] . Whereas tradi-
tional cognitive therapy  [28] focuses on directly modify-
ing dysfunctional thought  content through rational de-
liberation and guided discovery, ACT focuses on modify-
ing the person’s  relationship to his/her thinking more 
broadly. The goals of ACT are to promote increased ac-
ceptance of unavoidable distress, to cultivate a mindful 
outlook (i.e. awareness of mental events as products of the 
mind rather than literal truths), to counteract excessive 
entanglement with cognitions and to work toward goals 
that are consistent with patients’ personal values to mo-
tivate change  [25] . To achieve these aims, ACT employs a 
variety of strategies, including the use of metaphors and 
stories to communicate treatment concepts and behav-
ioral exercises to increase a person’s willingness to con-
tact the discomfort that often accompanies change ef-
forts.
 ACT theorizes that psychopathology is largely the re-
sult of  experiential avoidance , which involves the overi-
dentification with and excessive negative evaluation of 
internal events (e.g. thoughts, emotions, memories), a 
concomitant unwillingness to experience them, and the 
resulting efforts made to control or escape from them 
that can interfere with functioning and lead to behavior 
inflexibility  [27, 29] . From a clinical perspective, patients 
high in experiential avoidance tend to engage in multiple 
maladaptive strategies in attempts to remove internal 
sources of distress, which often lead to increasing social 
isolation, obsessive rumination, suicidality and thought 
disturbance. Studies using clinical and nonclinical sam-
ples demonstrate that experiential avoidance is strongly 
correlated with various forms of psychopathology, in-
cluding depression  [29] . Research also suggests that 
chronic experiential avoidance may produce a paradoxi-
cal effect, in that attempts to escape or control unwanted 
private events may actually increase their frequency or 
intensity in the long run  [30] . The negative effect of avoid-
ance-based coping also has been implicated in psychosis. 
For example, Tait et al.  [31] found that a ‘sealing-over’ re-
covery style after acute psychosis predicted several nega-
tive outcomes independent of insight into illness. ‘Sealing 
over’ is defined as a coping method in which the patients 
minimize the significance of their psychotic symptoms 
and are disinterested in exploring aspects of the experi-
ence in treatment, which has been shown to predict in-
creased depression and impaired psychosocial function-
ing independent of the person’s insight into illness.
 Based on findings from an earlier trial  [32] , Gaudiano 
and Herbert  [33] tested the efficacy of ACT in a sample 
of hospitalized patients with psychotic symptoms, which 
included PD, schizophrenia, schizoaffective disorder and 
bipolar disorder. The patients were taught to increase 
their acceptance of unavoidable distress, to simply notice 
their psychotic symptoms without treating them as either 
true or false, and to identify and work toward personally 
valued goals despite their symptoms  [34] . In this pilot 
trial, 40 patients were randomly assigned to enhanced 
treatment as usual (ETAU) or ETAU plus individual ACT 
sessions, the number of which varied based on a patient’s 
length of stay (average 3 sessions). At hospital discharge, 
patients receiving ACT showed greater improvements in 
mood symptoms, hallucination-related distress and be-
lievability, illness disability and clinically significant 
change. The groups did not differ in the frequency of psy-
chotic symptoms reported and both groups showed sig-
nificant decreases from before to after treatment. Al-
though the sample size was only modest, the ACT group 
had a 38% reduction in rehospitalization rates compared 
with ETAU alone by 4-month follow-up.
 Treatment Response in Patients with PD 
 As a significant proportion of the sample in the ACT 
for psychosis study was diagnosed as having PD (ETAU 
+ ACT: n = 9, ETAU only: n = 9), we conducted secondary 
analyses to investigate whether these patients also bene-
fited from psychotherapy provided during hospitaliza-
tion. The subsample of patients diagnosed as having PD 
based on admission diagnosis was 56% female and 78% 
unmarried. The average age was 40 years old (SD = 12). 
All participants were African-American (n = 17) or His-
panic (n = 1). In addition, 22% were homeless and 56% 
were receiving disability compensation. The average 
length of hospital stay was 9 days (SD = 8) and the pa-
tients received an average of 3 ACT sessions. Most gradu-
ated high school or had an equivalency diploma (61%).
 Descriptive statistics for outcome measures are re-
ported in  table 1 . Because of the small sample size, we 
limited our analyses to clinically meaningful outcomes 
using nonparametric tests. The results indicated that 
44% of the PD patients in the ACT group showed clini-
cally significant improvement by discharge ( 6 2 SD 
change from before to after treatment) on Brief Psychiat-
ric Rating Scale (BPRS)  [35] total scores compared with 
0% of the ETAU only group,    2  = 5.14, p  ! 0.05. The rates 
of clinically significant change on BPRS mood symptoms 
subscale were 70% in the ACT group compared with 30% 
in the ETAU only group,    2  = 3.60, p = 0.058. No signifi-
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cant differences were found between the rates of clini-
cally significant change on BPRS positive symptoms sub-
scale (p = n.s.).
 The patients were asked to rate the frequency (1 = none 
to 7 = almost constant), believability (0 = none to 10 = 
total belief) and distress (0 = none to 10 = very severe) 
associated with their hallucinations using single-item 
Likert ratings. Mann-Whitney U tests were computed on 
change scores of hallucination ratings. Pre- to posttreat-
ment improvement in hallucination-related distress was 
significantly greater in the ACT group (mean = –2.4,
SD = 3.3) compared with the ETAU group (mean = 1.0, 
SD = 2.2), which worsened slightly, z = 1.97, p  ! 0.05. 
Three patients from each condition were rehospitalized 
over 4-month follow-up.
 It is important to note that the pilot trial was not with-
out limitations. First, treatment was delivered in a brief 
format exclusively while patients were hospitalized. Pa-
tients with severe conditions such as PD are likely to ben-
efit from continued treatment and follow-up after dis-
charge. Second, although the results obtained from symp-
tom measures were promising, assessors and hospital 
staff were not blind to treatment allocation. Third, the 
number of patients with PD in the sample was relatively 
small and diagnoses were not based on structured clini-
cal interviews. Finally, although rehospitalization rates 
were assessed 4 months after discharge, the longer-term 
effects of the intervention on symptoms and functioning 
were not assessed. It will be important for future research 
to evaluate the efficacy of ACT in larger samples of pa-
tients with PD using more stringent methodology.
 Considerations in the Psychological Treatment of PD 
 Given their documented and robust success in treating 
mood and psychotic disorders, CBT-based interventions 
appear promising for treating PD. However, we recom-
mend caution in inferring that treatments that work well 
with nonpsychotic depression will be equally effective 
with PD. As noted, our data suggest that patients with PD 
respond less well to traditional psychotherapy than those 
with nonpsychotic depression and thus may require spe-
cific adaptations for optimal results  [13] . Therefore, the 
following suggestions should be viewed as tentative and 
are subject to change based on much needed empirical 
verification. Although other forms of therapy may also 
prove efficacious (e.g. family therapy), we limit the cur-
rent discussion to CBT approaches.
 How Should Therapy Be Adapted? 
 Although a variety of common CBT techniques (e.g. 
cognitive restructuring, behavioral activation, problem 
solving, anxiety management techniques) may prove use-
ful for treating PD, adaptations may be necessary. For ex-
ample, the therapist should proceed cautiously and ten-
tatively with the cognitive restructuring element of tradi-
tional cognitive therapy when treating psychotic in 
contrast to nonpsychotic depression. Pursuing disputa-
tion strategies too early or vigorously can alienate the pa-
tient and cause premature termination  [36] . One poten-
tial advantage of acceptance-based models of CBT such 
as ACT is that they focus more on increasing acceptance 
of internal distress than altering putatively dysfunctional 
Table 1. Baseline and discharge scores for patients with PD treated in an inpatient hospital setting
ETAU (n = 9) ETAU + ACT (n = 9)
baseline discharge 62 SD  baseline discharge 62 SD 
BPRS (18-item)
Mood symptom subscale 25.181.9 18.784.9 3 (33) 27.082.1 18.084.2 7 (77)
Psychotic symptom subscale 10.082.5 8.482.3 0 (0) 9.983.7 7.282.3 1 (11)
Total 55.485.0 43.386.6 0 (0) 58.087.3 42.688.0 4 (44)
Self-ratings of hallucinations
Frequency 5.181.6 3.881.8 6.081.5 4.781.9
Distress 6.382.9 7.381.7 9.181.7 6.783.3
Believability 8.381.7 7.682.5 8.682.6 5.984.2
Values are means 8 SD. Figures in parentheses represent the percentage of patients. Clinically significant 
improvement defined as 62 SD change ().
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thinking patterns to promote behavior change. The two 
pilot studies of ACT for psychotic inpatients suggest that 
acceptance techniques targeting psychotic symptoms can 
be used with the majority of patients in the first session 
 [32, 33] . However, when employed during less acute peri-
ods of illness, traditional cognitive restructuring tech-
niques may help the patient to develop skills in identify-
ing and countering residual symptoms of psychosis to 
prevent more severe relapses  [36] . In addition, it is impor-
tant to consider potential cognitive deficits and limita-
tions, which frequently are problems in PD  [5] . The ther-
apist can help mitigate this issue by focusing more on 
concrete behavioral goals and strategies when dealing 
with severely ill patients. The therapist can further tailor 
treatments for patients with cognitive limitations by ex-
plaining treatment concepts using simpler language (e.g. 
use of metaphors and stories in ACT), reviewing session 
information frequently and providing visual aids and pa-
tient handouts/workbooks. 
 Should Therapy Be Delivered Sequentially or 
Concurrently? 
 Some may argue that patients hospitalized with PD 
will be too severely ill to benefit from ‘talk’ therapy. How-
ever, available research indicates that acutely ill patients 
with severe mood and psychotic disorders can in fact 
benefit from adjunctive psychosocial interventions  [21, 
22] . During our research, we found it appropriate to be-
gin therapy with most hospitalized patients when they 
were able to participate in other group therapy on the unit 
after initial psychiatric stabilization with medications. It 
is important to emphasize that psychiatric stabilization 
also is required for informed consent. Also, psychother-
apy should be provided only after consultation with the 
patient’s treating medical team. Regarding the treatment 
of outpatients, review of the literature suggests that con-
current pharmacotherapy and psychotherapy is appro-
priate for most patients  [21] , again assuming close con-
sultation with the treating psychiatrist. Further, it is im-
portant for the therapist to provide a therapeutic rationale 
that does not undermine the other somatic treatments 
that the patient may be receiving. For patients with severe 
mental illnesses, a diathesis-stress model of illness can be 
used to acknowledge the role of genetic and neurobio-
logical factors, yet account for environmental influences 
(e.g. stressors, learning history) and other psychological 
processes (e.g. experiential avoidance) affecting the pa-
tient’s course of illness  [36] .
A sequential approach also could be considered  [37] . 
After acute psychotic symptoms dissipate and antipsy-
chotic medication is withdrawn, psychotherapy can be 
instated to help patients monitor residual symptoms and 
to learn to cope more effectively with stressors to prevent 
symptom reoccurrence. Moreover, sequential treatment 
with mindfulness-based CBT has been shown to reduce 
relapse rates in those at high risk (i.e. with multiple past 
depressive episodes)  [38] and therefore may prove useful 
for those with PD, given the recurrent nature of the dis-
order.
 What Level of Therapist Skill Is Necessary? 
 An additional consideration is the level of therapist 
skill necessary for treating patients with PD. Although 
many therapists may feel quite comfortable treating de-
pression, they may lack experience treating severely ill 
populations, including those experiencing psychosis. 
Some researchers are beginning to address this issue. A 
recent study demonstrated that CBT for psychosis could 
be effectively provided by psychiatric nurses receiving 
minimal training  [39] . Seminars and workshops on CBT 
for severely ill populations are frequently offered at pro-
fessional conferences such as the annual meeting of the 
Association for Behavioral and Cognitive Therapies. We 
recommend that a therapist with experience treating pa-
tients using CBT for depression seek out additional train-
ing first and then obtain supervision from an experi-
enced professional familiar with these issues for initial 
cases.
 What Potential Problems Should Be Anticipated? 
 Patients with PD are 2–5 times more likely to have a 
history of suicide attempts  [2] . Ongoing assessment and 
monitoring of suicidality constitutes an important com-
ponent of treatment. Further, the therapist and patient 
should collaborate to develop a mutually agreed upon 
safety plan detailing actions to be taken in response to 
increased suicidal ideation. In addition, nonadherence to 
medication and other treatments is a frequent problem in 
PD  [15] . The therapist should routinely monitor the pa-
tient’s level of adherence to pharmacotherapy and psy-
chotherapy. The therapist can help the patient problem 
solve issues surrounding medication management and 
promote closer consultation with the treating psychia-
trist. Also, the involvement of a significant other to im-
prove treatment adherence is a commonly used strategy 
in behavioral interventions. We have found it useful to 
hold 1 or 2 joint sessions with significant others (e.g. 
spouse, parent, sibling) to discuss ways in which the fam-
ily can support the patient’s treatment goals.
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 Are There Any Contraindications? 
 We found the ACT intervention to be generally well 
tolerated by patients and supported by hospital staff. 
However, we recommend caution when using formal, in-
tensive meditation techniques with acutely ill psychotic 
patients, as some case reports suggest that intensive med-
itation may exacerbate psychosis  [40] . ACT employs a 
number of nonmeditation-based exercises that foster 
mindfulness using alternative techniques  [34] . Further, 
patients with PD may experience periods of acute illness 
that can make it difficult to proceed with the therapy. 
Therapy can be suspended until the patient is stabilized. 
During these periods, the therapist can collaborate with 
other providers to assess and monitor the patient to de-
termine the need for hospitalization. Finally, we recom-
mend tailoring therapy to patient severity so as not to 
overwhelm the individual with treatment goals and strat-
egies. For example, the typical 1-hour session may be di-
vided into 2 half-hour sessions during hospitalization or 
periods of acute illness.
 Considerations for Future Research 
 As the previous review highlights, there is an urgent 
need to conduct systematic research on the psychosocial 
treatment of PD. We believe that CBT-based interven-
tions, including newer acceptance-based approaches, are 
good candidates for further testing. As pharmacotherapy 
is considered the first-line treatment for PD, studies 
should first examine whether combined pharmacothera-
py and psychotherapy result in better outcomes than 
pharmacotherapy alone. If this can be confirmed, further 
research should be conducted to examine the possible 
mechanisms of action of effective psychological treat-
ments for PD. As PD is likely to be most prevalent in 
acutely ill samples, study designs that focus on the re-
cruitment of patients initially hospitalized may aid in en-
rollment efforts. However, ethical issues become even 
more salient when dealing with hospitalized patients, 
and protocol safeguards are necessary to ensure informed 
consent. Structured clinical interviews administered by 
trained diagnosticians should be used to assess patients 
for study inclusion, as PD is often difficult to differen-
tially diagnose. In addition, recent research suggests that 
the BPRS is a psychometrically sound instrument that 
has good sensitivity and specificity for assessing PD  [41] . 
Finally, it will be important for studies to employ a range 
of outcome measures (e.g. symptom severity, psychoso-
cial functioning, treatment adherence, long-term out-
comes) that assess clinically (in addition to statistically) 
significant improvement in order to determine the poten-
tial benefits of psychotherapy for PD. 
 Conclusion 
 Adjunctive, psychosocial treatments for patients with 
PD are urgently needed due to the increased risk of mor-
bidity and mortality associated with this population. Un-
fortunately, treatment development in this area currently 
is lacking, as patients with psychotic features have been 
excluded historically from psychotherapy trials of depres-
sion. Our pilot data suggest that patients with PD can ben-
efit from modified CBT approaches. However, further re-
search is needed to develop comprehensive adjunctive ap-
proaches for treating patients during all phases of illness.
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